The global bone broth protein market is anticipated to grow at a considerable CAGR of 5% during the forecast period (2022-2028). Consumers in high disposable income countries are spending high amount on plant-based and protein-rich supplements to maintain their health. This is motivating market players to expand their product portfolio with new products aiming at consumer satisfaction. The key players actively participate in the development of bone broth protein products due to growing demand from the consumer owing to its nutritional benefits.  This is the major factor accelerating the market growth. For instance, In October 2021, Cerebelly launched Bone Broth to their existing line of beloved puree pouches. With 5g of protein in every pouch, this new sub-line supports even the highest levels of protein required for optimal brain development in children 11+ months. 

The global wound care product market is anticipated to grow at a considerable CAGR of around 5.6% during the forecast period (2022-2028). Key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansions, and product innovations to remain competitive in the market and this is the key factors driving the market growth. 

The global caspofungin market is anticipated to grow at a significant CAGR of around 5% during the forecast years. Caspofungin is an anti-fungal drug used for the treatment of such diseases. It is also used for the treatment of fungal infection cases where other anti-fungal drugs including amphotericin B, and itraconazole do not work effectively. One of the major factors for the growth of the market is the increasing number of patients suffering from fungal infections including invasive candidiasis and invasive aspergillosis. 

The global cognitive and memory enhancer drugs market is expected to grow at a CAGR of 5.5 percent during the forecast period. Cognitive and memory enhancer drugs are supplements or medications that promote cognitive functional improvement. These are primarily used to treat patients with schizophrenia, stroke, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), or geriatric patients. 

 The global surface protein gp 120 market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in March 2021, Gilead Sciences Inc. and Merck have jointly entered into a partnership to co-develop and co-commercialize the long-acting and investigational treatment combinations of Lenacapvir and Islatravir in HIV.

The global ortho biological products market is anticipated to grow at a considerable CAGR of 4.3% during the forecast period (2022-2028). The growing utilization of biologic agents such as platelet-rich plasma and stem cell therapy along with the rise in cell-based matrices is expected to offer lucrative growth opportunities in the global ortho biological products market. Furthermore, increasing adoption of bone marrow aspirate concentrate, adipose-derived stromal cells, and autologous conditioned serum is also expected to boost the market.

The global high-affinity nerve growth factor receptor market is anticipated to grow at a significant CAGR of 5.4% during the forecast period 2022-2028. The major factor attributed to the growth of the market is the rising prevalence of atopic dermatitis across the globe. As per the information provided by the National Eczema Association which highlighted the fact that around 9.6 million US children under the age of 18 have atopic dermatitis, along with one-third have moderate to severe diseases, and childhood atopic dermatitis has steadily increased from 8% to 12% since 1997. 

The global nicotine patch market is anticipated to grow at a significant CAGR of 7.0% during the forecast period 2022-2028. The major factor attributed to the market growth is the increased awareness among people regarding smoking health hazards. Additionally, the major players in the global nicotine patch market are going for collaborations and mergers in order to develop new products and medications.  For instance, in January 2021, Johnson & Johnson donated nicotine patches to help thousands of Jordanians quit smoking during COVID-19. Through its partnership with the Access Initiative for Quitting Tobacco (AIQT, Johnson & Johnson Consumer Health donated its first-ever contribution of nicotine replacement treatment to Jordan's Ministry of Health). 

The global fampridine market is expected to grow at a significant rate during the forecast (2022-2028). The key companies operating in the industry are highly inclined to adopt numerous growth strategies including partnerships collaborations, mergers and acquisitions, geographical expansion, and new product introductions to fulfill the growing market demands that is the key factor driving the market growth For instance, in December 2018, Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., launched Dalfampridine Extended-release Tablets, 10 mg, the generic pharmaceutical equivalent to Ampyra, according to Hikma Pharmaceuticals PLC. Apart from these, the significant approvals to drug developed by market players is further helping in the market growth. Such as,  in May 2021, Bojian Company announced that Fampridine Sustained-Release Tablets had been approved by China's National Medical Products Administration for the treatment of multiple sclerosis (MS) in adult patients with a walking disorder. Fampridine sustained-release pills are the first medication in China to improve the walking capacity of adult MS patients. Fampridine sustained-release pills are among the first batch of clinically urgently needed international new medications. 

The global hyperthermia treatment for cancer market is anticipated to grow at a considerable CAGR of 5.9% during the forecast period (2022-2028). Increase in incidence of different types of cancer and rise in diagnosis rate are the key factors boosting the growth of the market. The most common cancers diagnosed in men are prostate, lung, and colorectal cancers which account for an estimated 43% while for women most common cancers are breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in 2020. Governments in developed countries such as the U.S. raise funds for cancer research to aid in the diagnosis and treatment.